To sign up for our free research reports and newsletters, visit http://beaconequityresearch.com/. For more information on our research programs, please contact: Jeff Bishop at editor@beaconequityresearch.com
PhytoMedical Technologies, Inc. (OTCBB: PYTO) Up 13.33% on Thursday
Detailed quote: http://beaconequityresearch.com/PYTO
December 20, 2007 - PhytoMedical Expands Scope of Patented Technology That Kills Cancer Cells
PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6.F), today announced that it has expanded the research and development of a novel class of anti-cancer agents which have a 'cytotoxic' or poisonous affinity for cancer cells.
These patented anti-cancer compounds are designed to bind more tightly to cancer cell DNA than many conventional anti-cancer drugs by a process called bis-intercalation or "double binding," much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.
"Initial studies using a leukemia cell line demonstrated that such double binding or intercalation stopped the replication of the DNA, and, ultimately, lead to the death of the cancer cells," states Mr. Greg Wujek, President, CEO of PhytoMedical Technologies, Inc. "The positive initial results and the strength of intellectual property surrounding the technology has given us the confidence to expand our research in order to improve upon the concept of bis-intercalation and the promise it holds for the control of cancer."
In response to the success of the studies, PhytoMedical's collaborating scientists are now synthesizing and testing new derivatives of these anti-cancer agents. Further tests of the "DNA binding" anti-cancer agents are planned for human cancer cell lines specific to glioblastoma (tumors related to the brain) and small cell lung cancer, both of which are associated with a high mortality rate.
Mr. Greg Wujek concludes, "Our goal is to identify the compound that demonstrate the greatest anti-cancer activity and successfully complete the preclinical steps required for an Investigational New Drug Application."
e.Digital Corporation (OTCBB: EDIG) Up 12.07% on Thursday
Detailed quote: http://beaconequityresearch.com/EDIG
December 20, 2007 - e.Digital on Pace for Record Fiscal Year Revenues
e.Digital Corporation (OTCBB: EDIG), a leading innovator of dedicated portable inflight entertainment (IFE) systems and patented flash memory-related technology, announced today that it is on track to report record revenues for its fiscal year ending March 31, 2008. The Company expects to report approximately $5 million in revenues through its fiscal third quarter ending December 31, 2007.
"Since launching eVU(TM) last year, twelve airlines have made our proprietary portable system their inflight entertainment choice," said Will Blakeley, president of e.Digital. "Our patented, proprietary and efficient core technology provides fundamental competitive advantages over consumer and PC-based devices including the ability to easily add features and customize eVU for
Blakeley continued, "While we intend to grow our portable
"Our intellectual property team is finalizing detailed legal and technical documentation to support additional Flash-R(TM) patent portfolio enforcement actions against a broad range of companies," added Blakeley. "To date, we have identified annual
Blakeley concluded, "We are very encouraged with the progress of our eVU business, and we are convinced our Flash-R patent portfolio provides the opportunity for substantial future revenues."
Paivis Corp (OTCBB: PAVC) Up 9.09% on Thursday
Detailed quote: http://beaconequityresearch.com/PAVC
December 20, 2007 - Trustcash Holdings, Inc. and Paivis, Corp. Announce Signing of Definitive Agreement and Plan of Merger
TRUSTCASH HOLDINGS, INC. ("TRUSTCASH") (OTCBB: TCHH) and PAIVIS, CORP. ("PAIVIS") (OTCBB: PAVC) today jointly announced their execution of a Definitive Agreement and Plan of Merger (the "Merger Agreement") pursuant to which TRUSTCASH has agreed, through a wholly-owned subsidiary, to acquire 100% of the issued and outstanding common shares of the PAIVIS, and PAIVIS has agreed, at the closing of the transaction, to become a wholly-owned subsidiary of TRUSTCASH. As consideration in the merger transaction, TRUSTCASH has agreed to exchange shares of its preferred stock ("the Issuable Shares") with PAIVIS's shareholders at an exchange ratio, under the Merger Agreement that values the PAIVIS shares at $0.65 per common share.
Greg Moss, the Chief Executive Officer of TRUSTCASH, commented, "With the execution of this Definitive Agreement TRUSTCASH moves forward our plan of being aggressive in our growth plans to build a significant operation under a synergistic direction for our shareholders. PAIVIS is a business that we believe has vast potential. It is currently a multimillion dollar operation that has a business plan which includes other acquisition candidates and a comprehensive strategy for growth and profit generation. We look forward to closing and welcoming the PAIVIS shareholders as TRUSTCASH shareholders and feel very strongly on the new combined entities moving forward."
Edwin Kwong, the Interim Executive Officer of PAIVIS, commented further, "The execution of this agreement results from the execution of the Board of Directors plan that we had implemented to move PAIVIS forward through mergers and acquisition for the future growth of the company, and ultimately for the enhancement of value for the PAIVIS shareholders. TRUSTCASH is a burgeoning company with a product that possesses immense potential; we feel this merger provides a great opportunity for our shareholders' growth prospects. We are very pleased with the valuation that we received from TRUSTCASH and feel it is fair for our shareholders. We look forward to the consummation of this transaction and moving forward rapidly to develop a path of success for the combined corporations."
The parties have agreed to use their best efforts to consummate the transaction by January 31, 2008, or as soon as practicable thereafter. Upon closing the combined entities would include Trustcash, Paivis, and Paivis's acquisition targets, Detroit Phone Cards, Inc, and AAAA Media Services, Inc. and produce a combined revenue stream of approximately $73,000,000 (unaudited).
The Merger Agreement, which includes all details of the transaction including the rights and preferences of the Issuable Shares will be filed by TRUSTCASH and PAIVIS as an exhibit to a Current Report on Form 8-K with the U.S. Securities and Exchange Commission as required. The Merger Agreement contains certain conditions precedent to consummation of the merger, including but not limited to, financing being secured by Trustcash, the audits of Paivis' acquisitions being completed, obtaining consents, providing certified lists of shareholders and delivery of certain due diligence and other corporate documents. The Merger Agreement provides detail of the rights and preferred shares of the Issuable Shares. The Merger Agreement amongst other terms and conditions further provides that TRUSTCASH will file a registration statement to register the Issuable Shares and that an application will be made to list the Issuable shares to trade.
Park Place Energy Corp. (OTCBB: PRPL) Up 4.35% on Thursday
Detailed quote: http://beaconequityresearch.com/PRPL
December 20, 2007 - Park Place Energy Announces Exploration Activity Update
Park Place Energy Corp. ("Park Place Energy" or the "Corporation") is pleased to announce that Terra Energy Corp. ("the Operator") of its Eight Mile North Field in Northeastern British Columbia, has informed the Corporation that completion of the cased potential Doig gas well, Terra et al Tower 14-5-81-17 W6M well (the "14-5 Option Well") has commenced. Subject to a successful completion being achieved, the Operator has further advised the Corporation that a pipeline to tie in the previously announced discovery Doig gas well, Terra et al Tower 7-8-81-17 W6M along with the 14-5 Option Well is being planned for construction in the first quarter of 2008. Plans are also underway to license a further Option Well. Park Place Energy has a 40% participating interest Before Payout, which is subject to a proportionate share of a 12% convertible gross overriding royalty payable to the Operator, and a 24% participating interest After Payout in the Eight Mile North Project Area.
Montello Resources Ltd., the operator of Park Place Energy's 5% interest in the John Bowen # 2 Well ("the Well") located in Morgan County Tennessee has advised the Corporation that they were unable to run any logs in the Well prior to casing it. The Well has been drilled and cased to a total depth of 9,557 feet which is one of the deepest test wells to be drilled in the State of
The Corporation further announces that after receiving the latest evaluation and interpretation of the EM survey over its Brighty Prospect in the
Park Place Energy's President & CEO Eric Leslie stated, "Although it was disappointing that we were unable to secure an Operator for our Brighty Project in the North Sea we are looking forward to receiving the completion results from our 14-5 Option Well at Eight Mile North as well as from our John Bowen # 2 Well in Tennessee.
HealthSport, Inc.(OTCBB: HSPO) Up 8.62% on Thursday
Detailed quote: http://beaconequityresearch.com/HSPO
December 20, 2007 - HealthSport Inc. Partners With FORTUNE 500 Company Henry Schein, Inc.
HealthSport, Inc.(OTCBB:HSPO) announced today that Henry Schein, Inc., the largest distributor of healthcare products and services to office-based practitioners in the combined North American and European markets, has agreed to promote and sell Enlyten(tm) PediaStrips(tm) (http://pediastrips.com/) as part of their portfolio. This innovative new product formulated by InnoZen, Inc., HealthSport's research and manufacturing facility, provides an edible film strip-delivery system that contains sodium, potassium and chloride. PediaStrips are designed to deliver these electrolytes to children who are at risk for dehydration due to vomiting or diarrhea. In addition to PediaStrips(tm), Henry Schein has also agreed to utilize their sales force to sell Enlyten SportStrips.
"It's exciting to be partnering with the largest distributor of healthcare products and services to office-based practitioners in the combined North American and European markets. Henry Schein's team of specialists will provide Enlyten PediaStrips with the expertise and professionalism needed to penetrate the medical group arena," stated Gary Thomas, HealthSport's V.P. of Sales.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN THIS DOCUMENT. ALL INFORMATION PROVIDED HERE IS MERELY INFORMATIONAL AND IS NOT INTENDED TO BE A RECOMMENDATION TO BUY OR SELL ANY SECURITY. YOU SHOULD CONSULT A LICENSED INVESTMENT PROFESSIONAL BEFORE MAKING ANY INVESTMENT DECISION. All material herein has been prepared by us based upon information believed to be reliable. The information contained herein is not guaranteed by us to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not always approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. We are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed or mentioned herein. Beacon Equity Research has been compensated a total of fifteen thousand dollars by Onyx Consulting for an enrollment of HealthSport in its research program. It is the policy of Beacon Research and its affiliates to sell any stock received for services, which may cause the stock price to become depressed. Our affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. We may sell shares for less than the target price given in this opinion, or at any time following the issuance of this announcement. We will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Beacon Research and its owners undertake no obligation to update such statements.
